物质信息
ID:68
名称和标识
IUPAC标准名
(3S)-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}-3-[(2S)-2-[(2S)-3-(1H-indol-3-yl)-2-(3-{[(2-methylpropoxy)carbonyl]amino}propanamido)propanamido]-4-(methylsulfanyl)butanamido]propanoic acid
别名
Pentagastrin
商标名
Peptavlon
IUPAC传统名
peptavlon
化合物性质
理化性质
疏水性(logP)
1.6
描述信息
Drug Groups
approved
Description
A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. [PubChem]
Indication
Used as a diagnostic aid for evaluation of gastric acid secretory function
Pharmacology
Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection.
Affected Organisms
Humans and other mammals
Biotransformation
Primarily hepatic
Absorption
Rapidly absorbed after parenteral administration.
Half Life
10 minutes or less
References
•
Weintraub HS, Rudolph A: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. Am J Ther. 2010 Jun 9.
[Pubmed]
External Links
分子图谱
暂无数据
点击上传数据
参考文献
• Weintraub HS, Rudolph A: Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. Am J Ther. 2010 Jun 9. Pubmed